Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05324865
Other study ID # Hasan kalyoncu University Omer
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2022
Est. completion date October 2022

Study information

Verified date April 2022
Source Hasan Kalyoncu University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Schizophrenia is a mental illness that progresses with delusions or hallucinations, causes changes in interpersonal communication, thoughts and behaviors, continues with recovery and repetitions, and in which the interpretation of reality is impaired. Drug treatment alone is not sufficient in schizophrenia, and it is known that negative symptoms continue even in patients with a good response to drug treatment. For this reason, complementary therapies, psychosocial approaches and rehabilitation in addition to drug therapy increase the effectiveness of the treatment.


Description:

Schizophrenia is a mental illness that progresses with delusions or hallucinations, causes changes in interpersonal communication, thoughts and behaviors, continues with recovery and repetitions, and in which the interpretation of reality is impaired. Drug treatment alone is not sufficient in schizophrenia, and it is known that negative symptoms continue even in patients with a good response to drug treatment. For this reason, complementary therapies, psychosocial approaches and rehabilitation in addition to drug therapy increase the effectiveness of the treatment.It is seen that the tension, the effects of stress, the state of anxiety, blood pressure, heart rate, lactic acid production, sensitivity to pain are reduced by performing relaxation exercises in a suitable environment, regularly and in accordance with the technique. Helps you think positively Studies involving patients with schizophrenia have also proven the beneficial effect of progressive relaxation, with positive changes observed through relieving anxiety, reducing psychological stress, and increasing psychological well-being.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date October 2022
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:• Being 18 years or older, - Having a confirmed diagnosis of schizophrenia for at least 6 months - Having the ability to communicate and read, - Volunteering to participate in the research. Exclusion Criteria:• Being closed to communication, - Not complying with the principle of voluntarism - Patients in acute exacerbation period

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Progressive Muscle Relaxation
Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hasan Kalyoncu University

Outcome

Type Measure Description Time frame Safety issue
Primary Individual Introductory Information Form Patients' personal information (age, gender, marital status, educational status, income status, employment status) and disease information (year of disease onset, is the drug treatment sufficient, does the drug take the drug regularly, is there a regular check-up, is there any substance addiction) (cigarette, alcohol), are there any non-drug treatment methods in the fight against the disease) constitute questions. 10 minute
Primary Warwick-Edinburgh Mental Well-Being Scale The scale consists of 14 positive items and has a 5-point Likert-type answer key. High scores from the scale indicate high mental well-being. 15 minute
Primary Psychiatric Rating Scale(PRS) This form consists of 18 items. The items of the scale are scored between 0-6. It shows that the severity of the disease increases as the scoring increases. 15 minute
See also
  Status Clinical Trial Phase
Completed NCT01354132 - N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis Phase 4
Recruiting NCT02388607 - Sustained Attention Abilities in Schizophrenia